# EndoGastric Solutions

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endogastric-solutions

- Industry: Medical Devices & Equipment
- Headquarters: Redmond, US
- Website: www.endogastricsolutions.com
- Total disclosed funding: $223M
- Latest round: Series I (May 28, 2019)
- Investors on record: 13

## About

Founded in 2003 and based in Washington, US, EndoGastric Solutions, Inc., formerly known as EsophyX, Inc., operates as a medical device company that develops incision-less trans-oral procedures for the treatment of upper gastrointestinal diseases. The company's technologies include EsophyX Device, a device designed to reconstruct the gastroesophageal valve (GEV) and help restore the GEV’s function as a reflux barrier; and SerosaFuse Fasteners, a device that is durable, non-absorbable, and biocompatible, minimizing local inflammation and allowing natural GI tissue repair.

## Funding rounds

- Series I, May 28, 2019, $15M — Accelmed
- Series I, Jul 10, 2018, $25M — Advanced Technology Ventures, Canaan Partners, Radius Ventures, Chicago Growth Partners, SightLine Partners, CRG, Evidity Health Capital
- Series H, May 12, 2015, $10M — Advanced Technology Ventures, Canaan Partners, Radius Ventures, Chicago Growth Partners, SightLine Partners, Flare Capital Partners
- Series G, May 6, 2014, $30M — Advanced Technology Ventures, Canaan Partners, Foundation Medical Partners, Radius Ventures, De Novo Ventures, Chicago Growth Partners, Oakwood Medical Investors
- Series F, Jun 21, 2012, $13M — Advanced Technology Ventures, Canaan Partners, Foundation Medical Partners, Radius Ventures, De Novo Ventures, Chicago Growth Partners, Oakwood Medical Investors
- Series F, Aug 30, 2010, $30M — Advanced Technology Ventures, Canaan Partners, Foundation Medical Partners, Radius Ventures, De Novo Ventures, Chicago Growth Partners, MPM BioImpact
- Series E, Jan 20, 2010, $22M — Advanced Technology Ventures, Foundation Medical Partners, De Novo Ventures, Chicago Growth Partners, Oakwood Medical Investors, MPM BioImpact
- Series D, Aug 29, 2007, $30M — Advanced Technology Ventures, Foundation Medical Partners, De Novo Ventures, Chicago Growth Partners, Oakwood Medical Investors, MPM BioImpact
- Series C, Feb 26, 2006, $32M — Advanced Technology Ventures, Foundation Medical Partners, Chicago Growth Partners, Oakwood Medical Investors, MPM BioImpact
- Series B, Aug 11, 2004, $12M — Advanced Technology Ventures, Foundation Medical Partners, MPM BioImpact
- Series A, Jun 4, 2003, $5M — Advanced Technology Ventures, MPM BioImpact

## Investors

- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series A, Series B, Series C, Series D, Series E, Series F, Series G, Series H, Series I
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C, Series D, Series E, Series F
- Foundation Medical Partners (https://capitalatlas.ai/funds/foundation-medical-partners) — Series B, Series C, Series D, Series E, Series F, Series G
- Chicago Growth Partners (https://capitalatlas.ai/funds/chicago-growth-partners) — Series C, Series D, Series E, Series F, Series G, Series H, Series I
- Oakwood Medical Investors (https://capitalatlas.ai/funds/oakwood-medical-investors) — Series C, Series D, Series E, Series F, Series G
- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series D, Series E, Series F, Series G
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series F, Series G, Series H, Series I
- Radius Ventures (https://capitalatlas.ai/funds/radius-ventures) — Series F, Series G, Series H, Series I
- SightLine Partners — Series H, Series I
- Flare Capital Partners (https://capitalatlas.ai/funds/flare-capital-partners) — Series H
- CRG — Series I
- Evidity Health Capital (https://capitalatlas.ai/funds/evidity-health-capital) — Series I
- Accelmed (https://capitalatlas.ai/funds/accelmed) — Series I